Currently, anti-vascular endothelial growth factor (anti-VEGF) therapy is approved only for the treatment of the wet form of AMD and involves the inhibition of VEGF from binding to VEGF receptors in the retina. Here, VEGFA is linked to age-related macular degeneration.